北大医药: 关于同意公司配合参股公司减资及拟启动清算解散工作的公告

Core Viewpoint - The company has agreed to cooperate with its investee company, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., in reducing its registered capital and initiating liquidation due to severe operational difficulties [1][2][4]. Summary by Sections Basic Situation Overview - The investee company has a registered capital of 300 million RMB, with the company holding a 41% stake, amounting to an investment of 41 million RMB [1][2]. - The registered capital will be reduced from 300 million RMB to 100 million RMB, maintaining the proportionate contributions of all shareholders [2][5]. Approval Process - The board of directors approved the proposal with a unanimous vote of 3 in favor, 0 against, and 0 abstentions [3][4]. - The supervisory board also approved the proposal with a unanimous vote of 5 in favor, 0 against, and 0 abstentions [5]. Impact on the Company - The reduction of capital and subsequent liquidation of the investee company is aimed at optimizing the company's investment layout and reducing operational risks, which is expected to protect the interests of all shareholders, including minority shareholders [4][5]. - The actions taken will not have a substantial impact on the company's overall business development and profitability [5].